Biogen CEO Michel Vounatsos told CNBC on Wednesday that he is “reasonably confident” the U.S. Food and Drug Administration will approve the drugmaker’s experimental Alzheimer’s drug.
“We worked in full transparency with the regulator,” Vounatsos told “Squawk Box,” emphasizing the FDA has all of the company’s data on the drug.
“The evidence came over time. We collected a tremendous and complex set of data, including biomarkers and imaging,” he said. “This was a thorough engagement, and as CEO I’m reasonably confident this will lead to market approval one day.”
